The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

S, Principal Investigator at A*STAR SRL are co-authors of the study. While the current study focuses on basal cell carcinoma (BCC), researchers believe the technology could also be adapted to ...

Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

In 2016, 252,500 new cases of EC were diagnosed, and 193,900 patients died from EC in China (2). Squamous cell carcinoma (SCC) is the main histological subtype in China, making up around 90% of newly ...

in the treatment of basal cell carcinoma (BCC), with positive data outcomes. The study included patients who had relapsed after standard therapies and had no other treatment options. Among them, three ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

Notably, 27.3% (6 patients) had also failed second-line PD-1 inhibitors such as Libtayo or Keytruda ... in the Treatment of Basal Cell Carcinoma(BCC), with positive data outcomes. The study included ...

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.